Showing 1 - 10 of 12,010
Persistent link: https://www.econbiz.de/10002103016
Objectives: Many European countries regulate the markets for prescription drugs in order to cope with rising health expenditures. On the other hand, regulation distorts incentives to invest in pharmaceutical R&D. This study aims at empirically assessing the impact of regulation on pharmaceutical...
Persistent link: https://www.econbiz.de/10010526909
Persistent link: https://www.econbiz.de/10011708133
Persistent link: https://www.econbiz.de/10000572311
Persistent link: https://www.econbiz.de/10003937245
Persistent link: https://www.econbiz.de/10001681733
to health care, including pharmaceuticals. Given pressure on public budgets and rising expenditure for healthcare …, national governments have introduced mechanisms to regulate healthcare services provision and set prices of pharmaceuticals. As … pharmaceuticals and, in particular, its price-setting system. The bill endorsed by the German parliament in late 2010 will …
Persistent link: https://www.econbiz.de/10013018181
The article deals with the intersection between competition law rules on abuse of a dominant position and switching strategies employed by pharmaceutical originator companies. Switching is also known as ever-greening, product hopping or product life cycle strategies. It is one of the most...
Persistent link: https://www.econbiz.de/10013077034
EU countries closely regulate pharmaceutical prices whereas the U.S. does not. This paper shows how price constraints affect the profitability, stock returns, and R&D spending of EU and U.S. firms. Compared to EU firms, U.S. firms are more profitable, earn higher stock returns, and spend more on...
Persistent link: https://www.econbiz.de/10012465985
Persistent link: https://www.econbiz.de/10002946295